• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Full-length dystrophin restoration by in vivo RNA editing via a minidCas13X.1 conjugated ADAR

Research Project

Project/Area Number 22KF0410
Project/Area Number (Other) 22F22414 (2022)
Research Category

Grant-in-Aid for JSPS Fellows

Allocation TypeMulti-year Fund (2023)
Single-year Grants (2022)
Section外国
Review Section Basic Section 52020:Neurology-related
Research InstitutionNational Center of Neurology and Psychiatry

Principal Investigator

青木 吉嗣  国立研究開発法人国立精神・神経医療研究センター, 神経研究所 遺伝子疾患治療研究部, 部長 (80534172)

Co-Investigator(Kenkyū-buntansha) SAIFULLAH SAIFULLAH  国立研究開発法人国立精神・神経医療研究センター, 神経研究所 遺伝子疾患治療研究部, 外国人特別研究員
SAIFULLAH  国立研究開発法人国立精神・神経医療研究センター, 神経研究所 遺伝子疾患治療研究部, 外国人特別研究員
Project Period (FY) 2023-03-08 – 2024-03-31
Project Status Discontinued (Fiscal Year 2023)
Budget Amount *help
¥2,400,000 (Direct Cost: ¥2,400,000)
Fiscal Year 2024: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 2023: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 2022: ¥600,000 (Direct Cost: ¥600,000)
KeywordsRNA編集 / 筋ジストロフィー / Duchenne型筋ジスト ロフィー
Outline of Research at the Start

RNA編集はゲノム編集と異なり、ゲノムに対するオフターゲット変異挿入のリスクが無いことから、DMD遺伝子変異が原因のDuchenne型筋ジストロフィーの新規治療法として期待されている。本研究では、細胞およびマウスを対象に、DMD遺伝子のナンセンス変異を新規mini dCas 13X.1-ADAR1システムを用いたRNA編集により修復し、マウス骨格筋において全長ジストロフィンの発現を回復させることを目的とする。マウス骨格筋におけるRNA編集効率やジストロフィン発現レベルの評価に加えて、安全性についても評価する。

Outline of Annual Research Achievements

We changed nonsense codon (TAA) into sense codon (TGG) by using minidCas13X.1 and ADAR editor to the target site of the DMD transcript in a sequence-specific manner with the help of complementary guide RNAs. As a progress, we have made seven retroviral vectors (four guide RNAs vectors, two ADAR vectors with minidCas13X.1 and MS2 protein, one EGFP) and confirmed by sanger sequencing. To confirm the expression and retroviral packaging, we transduce the EGFP vectors into h2kmdx23 primary myoblast cells isolated from mdx23 mouse. The 70% cells have shown EGFP florescence according to microscopical observation. Which indicated that viral vector construction and packaging are good enough for next experiment. However, we have not yet checked the editing event in the cellular system.

Report

(2 results)
  • 2023 Annual Research Report
  • 2022 Annual Research Report
  • Research Products

    (3 results)

All 2022

All Journal Article (3 results) (of which Int'l Joint Research: 3 results,  Peer Reviewed: 3 results,  Open Access: 3 results)

  • [Journal Article] Development of Therapeutic RNA Manipulation for Muscular Dystrophy2022

    • Author(s)
      Saifullah, Norio Motohashi, Toshifumi Tsukahara, Yoshitsugu Aoki
    • Journal Title

      Front Genome Ed

      Volume: 4 Pages: 863651-863651

    • DOI

      10.3389/fgeed.2022.863651

    • Related Report
      2023 Annual Research Report 2022 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Integrated analysis of the clinical consequence and associated gene expression of ALK in ALK-positive human cancers.2022

    • Author(s)
      Saifullah, Tsukahara T.
    • Journal Title

      Heliyon

      Volume: 8 Issue: 7 Pages: e09878-e09878

    • DOI

      10.1016/j.heliyon.2022.e09878

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Integrated analysis of ALK higher expression in human cancer and downregulation in LUAD using RNA molecular scissors2022

    • Author(s)
      Saifullah, Tsukahara T.
    • Journal Title

      Clin Transl Oncol.

      Volume: 24 Issue: 9 Pages: 1785-1799

    • DOI

      10.1007/s12094-022-02835-6

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research

URL: 

Published: 2022-11-17   Modified: 2024-12-25  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi